NCT03021486View on ClinicalTrials.gov

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 5, 2017

Primary Completion Date

June 5, 2021

Study Completion Date

June 30, 2027

Conditions
Advanced Malignant NeoplasmDeliriumLocally Advanced Malignant NeoplasmMetastatic Malignant NeoplasmRecurrent Malignant Neoplasm
Interventions
DRUG

Chlorpromazine

Given IV

DRUG

Haloperidol

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Nursing Research (NINR)

NIH

lead

M.D. Anderson Cancer Center

OTHER